LH

Laboratory
D

LH

Arincen56/100B

Laboratory balance sheet 1989–2026

Laboratory had 261.80M USD in cash and short-term investments on 30 September 2026, against total debt of 6.78B USD: net debt of 6.51B USD.

Total assets Total liabilities Shareholders' equity

Click a line's chart icon in the table to add it to the chart; hover over it for a quick look.

Fiscal year
Latest
Q3 FY2026
FY2025
31 Dec 2025
FY2024
31 Dec 2024
FY2023
31 Dec 2023
FY2022
31 Dec 2022
FY2021
31 Dec 2021
FY2020
31 Dec 2020
FY2019
31 Dec 2019
FY2018
31 Dec 2018
FY2017
31 Dec 2017
FY2016
31 Dec 2016
Cash and equivalents
261.80M532.30M1.52B536.80M320.60M1.47B1.32B337.50M426.80M316.60M433.60M
Short-term investments
0.000.000.000.000.000.000.000.000.000.000.00
261.80M532.30M1.52B536.80M320.60M1.47B1.32B337.50M426.80M316.60M433.60M
Cash growth
-56.23%-64.95%+182.92%+67.44%-78.23%+11.50%+291.35%-20.92%+34.81%-26.98%-39.48%
Receivables
2.56B2.26B2.10B2.10B2.00B2.98B3.02B2.03B1.86B1.85B1.52B
Inventory
538.40M534.70M493.20M474.60M470.60M401.40M423.20M244.70M237.30M227.60M205.20M
Other current assets
0.001.00697.60M655.30M1.84B0.000.000.000.0088.90M148.30M
Total current assets
3.97B4.02B4.81B3.77B4.63B5.33B5.13B2.98B2.84B2.68B2.48B
Property, plant and equipment
3.14B3.08B3.05B2.91B2.79B2.82B2.73B2.61B1.78B1.75B1.72B
Long-term investments
128.30M153.90M16.30M26.90M65.70M60.90M73.50M84.90M60.50M58.40M57.60M
Goodwill and intangibles
10.89B10.39B9.86B9.48B9.25B11.69B11.71B11.90B11.27B11.87B9.82B
Goodwill
7.18B6.79B6.37B6.14B6.12B7.96B7.75B7.87B7.36B7.53B6.42B
Intangible assets
3.72B3.60B3.49B3.34B3.12B3.74B3.96B4.03B3.91B4.34B3.40B
Other non-current assets
793.40M751.30M652.20M536.50M3.42B462.60M410.00M435.40M276.00M605.30M165.10M
Total assets
18.92B18.39B18.38B16.73B20.16B20.39B20.07B18.02B16.19B16.57B14.25B
Accounts payable
738.00M840.80M875.80M827.50M852.20M621.30M638.90M632.30M634.60M573.90M508.40M
Deferred revenue
402.60M439.10M392.20M421.70M310.60M558.50M506.50M451.00M356.40M380.80M176.00M
Short-term debt
601.20M695.80M1.00B999.80M301.30M1.50M376.70M415.20M10.00M409.20M541.10M
Other current liabilities
0.00847.80M495.40M431.40M1.10B735.50M623.20M474.60M427.60M432.80M346.20M
Total current liabilities
2.82B2.82B3.33B3.23B3.08B2.78B3.08B2.66B1.88B2.19B1.83B
Long-term debt
5.25B5.77B5.33B4.05B5.04B5.42B5.42B5.79B5.99B6.29B5.24B
Other non-current liabilities
725.60M-34.80M517.40M409.30M642.40M402.00M526.40M383.20M334.00M442.30M392.00M
Lease obligations, current
187.70M0.00190.70M172.20M169.80M197.50M198.70M214.90M7.90M8.30M8.40M
Lease obligations, long-term
736.30M745.60M750.60M727.50M736.50M727.10M762.00M687.70M51.00M57.80M56.20M
Total liabilities
10.06B9.76B10.31B8.83B10.04B10.09B10.61B10.46B9.19B9.85B8.73B
Common stock and paid-in capital
7.30M7.50M7.60M7.70M8.10M8.50M9.00M9.00M11.70M12.00M12.10M
Retained earnings
8.91B8.64B8.30B7.89B10.58B10.46B9.48B7.90B7.08B6.22B4.96B
Accumulated other comprehensive income
-143.40M-27.60M-261.60M-59.30M-493.20M-192.00M-161.90M-372.40M-463.10M-335.70M-581.10M
Shareholders' equity
8.85B8.62B8.05B7.88B10.10B10.27B9.44B7.57B6.97B6.80B5.51B
Minority interest
16.10M16.90M14.30M15.50M18.90M20.60M20.70M20.10M19.10M20.80M15.20M
6.78B7.20B7.27B5.95B6.25B6.34B6.76B7.11B6.06B6.76B5.85B
Net cash
-6.51B-6.67B-5.75B-5.42B-5.93B-4.87B-5.44B-6.77B-5.63B-6.45B-5.42B
Working capital
1.15B1.20B1.48B540.20M1.55B2.55B2.05B325.40M956.50M496.90M651.10M
Book value per share
108.43102.8695.4189.90110.22105.3796.2976.7467.9565.4952.79
Tangible book value
-2.05B-1.77B-1.81B-1.61B850.00M-1.42B-2.28B-4.33B-4.30B-5.07B-4.32B
Tangible book value per share
-25.08-21.07-21.40-18.379.28-14.57-23.22-43.94-41.91-48.77-41.41
Current ratio
1.411.421.441.171.501.921.661.121.511.231.36
Debt to equity
0.770.840.900.760.620.620.720.940.870.991.06

Figures in USD at the end of each period. Net cash is cash and short-term investments less total debt; book value per share is on the diluted share count. The latest column is the most recent quarter.

Common questions about Laboratory's cash and debt

Source: Financial Modeling Prep

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.